terahydro-1,4-thiazine carboxylic acid methyl ester | 78865-47-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: terahydro-1,4-thiazine carboxylic acid methyl ester
• 英文别名: methyl 1,4-tetrahydrothiazine-3-carboxylate；tetrahydro-1,4-thiazine-3-carboxylic acid；methyl thiomorpholine-3-carboxylate；Thiamorpholin-3-carbonsaeure-methylester
• CAS: 78865-47-1
• 化学式: C₆H₁₁NO₂S
• mdl: MFCD09405990
• 分子量: 161.225
• InChiKey: CYKUMLWZCRVBJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  terahydro-1,4-thiazine carboxylic acid methyl ester 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以96%的产率得到3-硫代吗啉甲酰肼
  参考文献：
  名称：

  杂环α-亚氨基羧酸的衍生物。1.杂环α-亚氨基羧酸酰肼及其的合成

  摘要：

  DOI：

  10.1007/bf00534398
• 作为产物：
  描述：

  2,3-二溴丙酸甲酯 、 半胱胺盐酸盐 在 三乙胺 作用下， 以 乙醇 为溶剂， 以48%的产率得到terahydro-1,4-thiazine carboxylic acid methyl ester
  参考文献：
  名称：

  硫代吗啉-羧酸酯的非对映异构体的合成与分离

  摘要：

  DOI：

  10.1007/bf00505757

文献信息

• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• Compounds, compositions, and methods for stimulating neuronal growth and elongation
  申请人：——

  公开号：US20020061881A1

  公开（公告）日：2002-05-23

  The present invention concerns methods, pharmaceutical compounds, and compositions for stimulating neuroite outgrowth in nerve cells leading to nerve regeneration. These methods, compounds and compositions inhibit rotamase enzyme activity associated with binding proteins.

  本发明涉及用于刺激神经元细胞中神经元生长的方法、药物化合物和组合物，从而导致神经再生。这些方法、化合物和组合物抑制了与结合蛋白相关的旋转酶酶活性。
• N-Substituted Thiomorpholine Derivatives as the Inhibitors of Dipeptidyl Peptidase IV and the Pharmaceutical Uses Thereof
  申请人：Li Song

  公开号：US20100113433A1

  公开（公告）日：2010-05-06

  The present invention relates to N-Substituted thiomorpholine compounds of formula I, the possible isomers, the pharmaceutically acceptable salts, the solvates, the hydrates or the prodrugs thereof as inhibitors of dipeptidyl peptidase IV (DPP-IV); and to a method for preparing the compounds of formula I, pharmaceutical compositions comprising the compounds of formula I and use of the compounds of formula II in medical field, particularly in the preparation of medicaments for treating and preventing diabetes (in particular type II diabetes), hyperglycemia, X syndrome, hyperinsulinemia, obesity, atherosclerosis and all kinds of diseases modulated by immune system.

  本发明涉及公式I的N-取代硫代吗啡烷化合物、可能的异构体、药学上可接受的盐、溶剂化物、水合物或其前药，作为二肽酰胺酶IV（DPP-IV）的抑制剂；以及制备公式I化合物的方法、包含公式I化合物的制药组合物和在医学领域中使用公式II化合物的用途，特别是在制备用于治疗和预防糖尿病（特别是2型糖尿病）、高血糖、X综合症、高胰岛素血症、肥胖症、动脉硬化和所有由免疫系统调节的各种疾病的药物中。
• Pyrazole derivative
  申请人：Kanaya Naoaki

  公开号：US20060128685A1

  公开（公告）日：2006-06-15

  The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.

  本发明旨在提供一种强的血小板聚集抑制剂，其不抑制COX-1或COX-2。本发明提供了由式（I）或式（II）表示的化合物，化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂，其中包含任何一种化合物、盐或溶剂。
• Five-membered heterocyclic derivative
  申请人：Okayama Toru

  公开号：US20060189591A1

  公开（公告）日：2006-08-24

  The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor containing any of the compounds, the salts, and the solvates. The compound of the present invention is useful as a strong platelet coagulation inhibitor without inhibiting COX-1 or COX-2.

  本发明涉及一种由公式（I）表示的化合物：该化合物的盐，或该化合物或盐的溶剂化物；含有任何该化合物、盐和溶剂化物的药物；含有任何该化合物、盐和溶剂化物的缺血性疾病的预防和/或治疗剂；以及含有任何该化合物、盐和溶剂化物的血小板凝集抑制剂。本发明的化合物在不抑制COX-1或COX-2的情况下作为强效的血小板凝集抑制剂非常有用。